Sphere Fluidics
Sphere Fluidics’ platforms are built on over a decade of scientific and engineering research and development. Originally spun out from the University of Cambridge, they specialize in single-cell analysis and isolation platforms – helping you to find your really important cells.
Latest Sphere Fluidics Content
Product News
Sphere Fluidics Announces Cyto-Mine Chroma To Accelerate and Streamline Workflows Across Expanded Applications in Biotherapeutic Discovery and Development
Sphere Fluidics, a leading provider of innovative droplet-based microfluidics solutions for single-cell analysis and isolation, today shared details of Cyto-Mine® Chroma, the second generation of its flagship Cyto-Mine platform.
Online Event
Advances in Drug Discovery & Development 2024
On-Demand
This online event is aimed at those working within academia and pharmaceutical drug development, who want to hear from experts across their field. Focus will be given to the latest advances in small molecule drug discovery and development.
Video
Accelerating Single-Cell Analysis and Screening with the Power of Picodroplets
In this Teach Me in 10 video, we'll explore the acceleration of single-cell analysis and screening within the drug discovery process.
Article
High-Throughput Screening: Advances, Applications and Combined Approaches
In this article, we highlight various high-throughput screening strategies being used to interrogate large libraries of compounds and hear from researchers working to further streamline specific approaches to increase speed and improve quality and accuracy.
Product
Advertisement
Cyto-Mine®: Single Cell Analysis and Monoclonality Assurance System
Cyto-Mine® can simplify and accelerate your day-to-day operations in cell line development, antibody discovery, and beyond. It’s powered by our picodroplet technology to screen and analyze millions of individual cells and isolate those rare ‘hits’ with monoclonality assured. And all in a single, integrated platform with minimal ‘hands-on’ time.
App Note / Case Study
Screen Single Cells in Their Own Microenvironment
This app note highlights a uniquely protective environment to support cell viability and integrity during incubation and shield cells against shear stress during subsequent analysis.
Webinar
Accelerating Cell Line Development From Transfection to Manufacturing
On-Demand
Generating a highly expressing, regulatory compliant clonal cell line is key when developing a biopharmaceutical. Yet cell line development is labor-intensive, time consuming and costly.
The production of a high-quality and productive cell line requires both an expression system which yields high expressing clones and a workflow which allows selection of the highest producing clones.
In this webinar, you’ll discover how combining a single-cell analysis platform with a novel glutamine synthetase-Chinese hamster ovary (GS-CHO) expression system can yield highly productive, scalable, clonal cell lines for developing biopharmaceuticals.
The production of a high-quality and productive cell line requires both an expression system which yields high expressing clones and a workflow which allows selection of the highest producing clones.
In this webinar, you’ll discover how combining a single-cell analysis platform with a novel glutamine synthetase-Chinese hamster ovary (GS-CHO) expression system can yield highly productive, scalable, clonal cell lines for developing biopharmaceuticals.
Product News
Sphere Fluidics’ Cyto-Mine System Selected by FairJourney Biologics To Advance Cell Line Development Workflows
Investment to expand cell line development capabilities and accelerate customer workflows, as part of its diverse and tailored antibody solutions.
Product News
Sphere Fluidics Expands Cyto-Mine Capabilities To Meet cGMP Requirements for Drug Manufacture Workflows
Sphere Fluidics has announced updates to its flagship platform, Cyto-Mine®, enabling it to be compliant with current Good Manufacturing Practice regulations enforced by the US FDA.
Product News
Sphere Fluidics’ Pico-Mine platform chosen by Biosyntia to accelerate synthetic biology and metabolic workflows
Sphere Fluidics announced Biosyntia, a biotechnology company focused on synthetic biology and metabolic engineering, has adopted the Pico-Mine® platform within its workflows.
Advertisement